These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10611628)

  • 1. Phytanic acid storage disease (Refsum's disease): clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management.
    Weinstein R
    J Clin Apher; 1999; 14(4):181-4. PubMed ID: 10611628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term strategies for the treatment of Refsum's disease using therapeutic apheresis.
    Zolotov D; Wagner S; Kalb K; Bunia J; Heibges A; Klingel R
    J Clin Apher; 2012; 27(2):99-105. PubMed ID: 22267052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange for Refsum's disease.
    Gibberd FB
    Transfus Sci; 1993 Jan; 14(1):23-6. PubMed ID: 10150979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Refsum's disease: evolution 35 years after diagnosis].
    Marcaud V; Defontaines B; Jung P; Degos CF
    Rev Neurol (Paris); 2002 Feb; 158(2):225-9. PubMed ID: 11965181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
    Wierzbicki AS; Lloyd MD; Schofield CJ; Feher MD; Gibberd FB
    J Neurochem; 2002 Mar; 80(5):727-35. PubMed ID: 11948235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heredopathia atactica polyneuritiformis phytanic-acid storage disease, Refsum's disease:" a biochemically well-defined disease with a specific dietary treatment.
    Refsum S
    Arch Neurol; 1981 Oct; 38(10):605-6. PubMed ID: 6170281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Refsum disease].
    Hochner I; Blickle JF; Brogard JM
    Rev Med Interne; 1996; 17(5):391-8. PubMed ID: 8763099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heredopathia atactica polyneuritiformis: Refsum's disease.
    Gibberd FB; Billimoria JD; Goldman JM; Clemens ME; Evans R; Whitelaw MN; Retsas S; Sherratt RM
    Acta Neurol Scand; 1985 Jul; 72(1):1-17. PubMed ID: 2413704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders related to the metabolism of phytanic acid.
    Stokke O; Skjeldal OH; Høie K
    Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution of phytanic acid and its analogues in a kinship with Refsum's disease.
    Yao JK; Dyck PJ
    Lipids; 1987 Feb; 22(2):69-75. PubMed ID: 2436023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heredopathia atactica polyneuritiformis (Refsum's disease): 1. Clinical features and dietary management.
    Masters-Thomas A; Bailes J; Billimoria JD; Clemens ME; Gibberd FB; Page NG
    J Hum Nutr; 1980 Aug; 34(4):245-50. PubMed ID: 6157716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation.
    Skjeldal OH; Stokke O; Refsum S; Norseth J; Petit H
    J Neurol Sci; 1987 Jan; 77(1):87-96. PubMed ID: 2433405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of phytanic acid in Refsum's disease.
    Billimoria JD; Clemens ME; Gibberd FB; Whitelaw MN
    Lancet; 1982 Jan; 1(8265):194-6. PubMed ID: 6172683
    [No Abstract]   [Full Text] [Related]  

  • 14. Infantile Refsum's disease (phytanic acid storage disease): a variant of Zellweger's syndrome?
    Poulos A; Sharp P; Whiting M
    Clin Genet; 1984 Dec; 26(6):579-86. PubMed ID: 6209040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refsum's disease: management by diet and plasmapheresis.
    Hungerbühler JP; Meier C; Rousselle L; Quadri P; Bogousslavsky J
    Eur Neurol; 1985; 24(3):153-9. PubMed ID: 2581787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heredopathia atactica polyneuritiformis. Hexadecanoic acid storage disease (Refsum's disease). Definition, treatment and pathogenesis. A short review].
    Refsum S
    Psychiatr Neurol Med Psychol Beih; 1977; 22-23():11-8. PubMed ID: 95656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
    Wierzbicki AS
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):881-6. PubMed ID: 17956237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.
    Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM
    Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane differential filtration is safe and effective for the long-term treatment of Refsum syndrome--an update of treatment modalities and pathophysiological cognition.
    Straube R; Gäckler D; Thiele A; Muselmann L; Kingreen H; Klingel R
    Transfus Apher Sci; 2003 Aug; 29(1):85-91. PubMed ID: 12877898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A child with Refsum's disease: successful treatment with diet and plasma exchange.
    Dickson N; Mortimer JG; Faed JM; Pollard AC; Styles M; Peart DA
    Dev Med Child Neurol; 1989 Feb; 31(1):92-7. PubMed ID: 2465931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.